Alkem Laboratories Intrinsic Value
Alkem Laboratories (ALKEM) median intrinsic value is ₹9282.55 from 9 valuation models (range ₹1638–₹10903), vs current price ₹5451.50 — +70.3% upside (Trading Below Calculated Value), margin of safety 41.3%. Browse ALKEM complete financial statements for revenue, profit, balance sheet and cash flow data.
ALKEM Valuation Methods Summary — DCF, Graham Number & P/E
Alkem Laboratories intrinsic value across 9 models vs current price ₹5451.50 — upside/downside and value range per method. Also explore ALKEM share price data to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹5631.12 | ₹4504.90 - ₹6757.34 | +3.3% | EPS: ₹255.96, Sector P/E: 22x |
| Book Value Method | asset | ₹10361.67 | ₹9325.50 - ₹11397.84 | +90.1% | Book Value/Share: ₹5180.83, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹10903.00 | ₹9812.70 - ₹11993.30 | +100.0% | Revenue/Share: ₹6841.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹10903.00 | ₹9812.70 - ₹11993.30 | +100.0% | EBITDA: ₹4100.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹9282.55 | ₹7426.04 - ₹11139.06 | +70.3% | CF Growth: 10.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹1638.14 | ₹1474.33 - ₹1801.95 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹3954.58 | ₹3559.12 - ₹4350.04 | -27.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹10903.00 | ₹9812.70 - ₹11993.30 | +100.0% | ROE: 25.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹5462.32 | ₹4916.09 - ₹6008.55 | +0.2% | EPS: ₹255.96, BVPS: ₹5180.83 |
ALKEM Intrinsic Value vs Market Price — All Valuation Models
Alkem Laboratories fair value range ₹1638–₹10903 vs current market price ₹5451.50 across 9 valuation models. For current market price and key ratios, visit Alkem Laboratories share price today.
ALKEM Intrinsic Value Analysis — Undervalued or Overvalued?
Alkem Laboratories median intrinsic value ₹9282.55, current price ₹5451.50 — Trading Below Calculated Value by 70.3%, margin of safety 41.3%.
What is the intrinsic value of ALKEM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Alkem Laboratories (ALKEM) is ₹9282.55 (median value). With the current market price of ₹5451.50, this represents a +70.3% variance from our estimated fair value.
The valuation range spans from ₹1638.14 to ₹10903.00, indicating ₹1638.14 - ₹10903.00.
Is ALKEM undervalued or overvalued?
Based on our multi-method analysis, Alkem Laboratories (ALKEM) appears to be trading below calculated value by approximately 70.3%.
ALKEM Financial Health — Key Ratios vs Industry Benchmarks
Alkem Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.32 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 25.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.93x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ALKEM Cash Flow Quality — Operating & Free Cash Flow
Alkem Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,913 Cr | ₹1,269 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,948 Cr | ₹1,443 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,683 Cr | ₹1,683 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,111 Cr | ₹395 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1,265 Cr | ₹768 Cr | Positive Free Cash Flow | 8/10 |